Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 11/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530570 | 0.89 | LRRK2 (0.41) | STAT3HPGDKDM4EALDH1A1POLB | |
| SCHEMBL18542146 | 0.88 | KMO (0.43) | STAT3PAK4HPGDKDM4EALDH1A1 | |
| SCHEMBL18530600 | 0.88 | STAT3 (0.42) | STAT3PAK4HPGDKDM4EALDH1A1 | |
| SCHEMBL18530534 | 0.85 | HPGD (0.42) | STAT3PAK4HPGDGABRA5VNN1 | |
| SCHEMBL16585117 | 0.82 | S1PR1 (0.41) | STAT3PAK4GABRA5HRH3 | |
| SCHEMBL16585093 | 0.82 | PAK4 (0.39) | STAT3PAK4HPGDKDM4EALDH1A1 | |
| SCHEMBL18704598 | 0.82 | HPGD (0.43) | STAT3PAK4HPGDHSD17B10GABRA5 | |
| SCHEMBL31622717 | 0.79 | GABRA5 (0.43) | STAT3PAK4GABRA5HRH3 | |
| SCHEMBL16585293 | 0.79 | PAK4 (0.39) | STAT3PAK4HPGDKDM4EALDH1A1 | |
| SCHEMBL16584923 | 0.79 | PAK4 (0.39) | STAT3PAK4HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218207-A1 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | Karyopharm Therapeutics Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-3337796-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017031213-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031213-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218207-A1 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | NAMPT, PAK3, PAK5 | STAT3 331/4885TRPV1 329/4885PAK4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.